What is the combination in Juluca?

Juluca is a fixed-dose combination medication used in the treatment of HIV-1 infection. It combines two active ingredients: dolutegravir and rilpivirine.

Dolutegravir is an integrase strand transfer inhibitor (INSTI) that works by preventing the integration of viral DNA into the host genome, thus inhibiting viral replication. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that inhibits reverse transcription, which is crucial for the virus to replicate.

The combination of these two agents in Juluca is significant because it allows for a simplified treatment regimen by providing two highly effective antiretroviral options in a single pill, which can enhance adherence to therapy and reduce pill burden for patients. This fixed-dose combination has proven effective in maintaining viral suppression in patients who are virologically suppressed on a stable antiretroviral regimen.

The other options presented are different combinations and do not constitute Juluca, making them irrelevant in this context.